POLYPEPTIDE GROUP AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.22 CHF | -0.97% |
|
+4.06% | +90.35% |
| Mar. 12 | PolyPeptide Group AG Provides Earnings Guidance for 2024 | CI |
| Mar. 12 | Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024 |
ETFs positioned on PolyPeptide Group AG
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 746 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +4.64% | - | |
| 0.00% | 146 M€ | -1.80% | - | |
| 0.00% | 25 M€ | 0.00% | - |
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
34.18
EUR
Average target price
25.12
EUR
Spread / Average Target
-26.49%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +90.35% | 1.22B | |
| +33.12% | 709B | |
| +30.77% | 595B | |
| -2.34% | 367B | |
| +20.08% | 334B | |
| +4.94% | 289B | |
| +14.23% | 239B | |
| +9.00% | 211B | |
| -3.64% | 203B | |
| +8.60% | 171B |
- Stock Market
- Equities
- PPGN Stock
- Funds and ETFs PolyPeptide Group AG